Aurobindo Receives FDA Approval for Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg
Published: January 12, 2022
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg . Aurobindo Pharma’s Nebivolol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic® Tablets, of Allergan Sales, LLC.
Nebivolol Tablets are indicated for:
- The treatment of hypertension.